EGFR-Targeted Therapy for NSCLC: Tolerability-Guided Dose Adjustment

EGFR-Targeted Therapy for NSCLC: Tolerability-Guided Dose Adjustment

Episodes

Specialty:

All

Year:

All

EP. 1: Mutation Testing for NSCLC in 2017

December 16th 2016

EP. 2: Options for Up-front Therapy in EGFR-mutant NSCLC

December 16th 2016

EP. 3: Efficacy and Safety of Afatinib vs Erlotinib and Gefitinib in EGFR+ NSCLC

December 16th 2016

EP. 4: Sequencing EGFR-Targeted Therapies in NSCLC

December 16th 2016

EP. 5: Tolerability-Guided Dose Adjustment of Afatinib in NSCLC

December 16th 2016

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma